243 related articles for article (PubMed ID: 28881389)
1. Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin.
Christiansen I; Markvardsen LH; Jakobsen J
Muscle Nerve; 2018 Apr; 57(4):610-614. PubMed ID: 28881389
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
5. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
7. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.
Misbah SA; Baumann A; Fazio R; Dacci P; Schmidt DS; Burton J; Sturzenegger M
J Peripher Nerv Syst; 2011 Jun; 16(2):92-7. PubMed ID: 21692906
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home.
Lucas M; Hugh-Jones K; Welby A; Misbah S; Spaeth P; Chapel H
J Clin Immunol; 2010 May; 30 Suppl 1():S84-9. PubMed ID: 20387103
[TBL] [Abstract][Full Text] [Related]
9. Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP.
Markvardsen LK; Bruun-Sørensen S; Christiansen I; Andersen H
PeerJ; 2019; 7():e6969. PubMed ID: 31143558
[TBL] [Abstract][Full Text] [Related]
10. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Markvardsen LH; Christiansen I; Jakobsen J
Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin.
Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK
Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions.
Bayas A; Gold R; Naumann M
J Neurol Sci; 2013 Jan; 324(1-2):53-6. PubMed ID: 23095259
[TBL] [Abstract][Full Text] [Related]
13. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
[TBL] [Abstract][Full Text] [Related]
15. Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Ricciardi D; Tedeschi G
Muscle Nerve; 2019 Dec; 60(6):662-667. PubMed ID: 31415091
[TBL] [Abstract][Full Text] [Related]
16. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T
J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187
[TBL] [Abstract][Full Text] [Related]
17. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
18. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
19. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.
Harbo T; Andersen H; Jakobsen J
Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs.
Markvardsen LH; Harbo T
J Neurol Sci; 2017 Jul; 378():19-25. PubMed ID: 28566163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
